Abstract

In selecting drug target candidates for pharmaceutical research, the linkage to disease and the tractability of the target are two important factors that can ultimately determine the drug efficacy. Several existing resources can provide gene-disease associations, but determining whether such a list of genes are attractive drug targets often requires further information gathering and analysis. In addition, few resources provide the information required to evaluate the tractability of a target. To address these issues, we have updated TargetMine, a data warehouse for assisting target prioritization, by integrating new data sources for gene-disease associations and enhancing functionalities for target assessment. As a data mining platform that integrates a variety of data sources, including protein structures and chemical compounds, TargetMine now offers a powerful and flexible interface for constructing queries to check genetic evidence, tractability and other relevant features for the candidate genes. We demonstrate these features by using several specific examples.

Highlights

  • A drug discovery project typically begins with the identification of a target molecule

  • In evaluating potential drug targets, several factors must be taken into account: linkage to disease, tractability, potential side effects, novelty, as well as the competitiveness in the market (Figure 1)

  • The linkage to disease and the tractability are important in terms of the drug efficacy, and become key factors in whether or not the pharmaceutical research and development (R&D) is successful when selecting drug targets[1,2]

Read more

Summary

28 Feb 2019

Any reports and responses or comments on the article can be found at the end of the article. To respond to the reviewers’ comments, in this revision, we enhance the explanation of the use cases. We incorporate an application for the pathway analysis in the use case section. We share the details of our analysis as extended data which can be found at OSF.

Introduction
Methods
Conclusions
Bunnage ME
30. Day IN
Findings
32. Chen YA

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.